Report: Canada Trails Similar Countries on New Drug Access
Wednesday, June 3, 2015
Source: FDA News
Canada lags significantly behind other developed countries in providing coverage for new medicines, with Canadians waiting on average 462 days for novel, potentially lifesaving drugs, a new report shows.
Overall, Canada ranks 16 out of 18 countries in the Organization for Economic Co-operation and Development in the length of time from marketing authorization of a new drug to reimbursement by public prescription drug plans. Time to listing in at least one province is 493 days, 217 days longer than the average and 238 more days than the median of all countries, the report by IMS Brogan says.